Fredun Pharmaceuticals Share Price

CMP as on17-May-22 15:00

₹ 996.15
47.4 5%

Open

₹ 995.00

Turnover (lac)

₹ 9

Prev. Close

₹ 948.75

Day's Vol (shares)

₹ 2,458

Day's Range

₹ 990.00
₹ 996.15

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 09-May-2022 - -
Fredun Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on May 16, 2022 inter alia, to consider and approve the following: 1. Audited Financial Results for the last quarter and financial year ended March 31, 2022 along with the Statement of Assets and Liabilities and Cash Flow statement as on that date. 2. Audited Financial Statements for the Financial Year ended March 31, 2022. 3. Recommend dividend for the Financial Year ended March 31, 2022 subject to the approval of the Shareholders at the ensuing Annual General Meeting of the Company. Further, in continuation of the intimation dated March 31, 2022 and pursuant to Companys Code of Conduct formed under the Securities and Exchange Board of India (Prohibition of Insider Trading Regulations, 2015 and amendments thereunder, the trading window for dealing in the securities of the Company has been closed from April 01, 2022 and it shall remain closed until fortyeight hours after the date of declaration of results for the quarter and year ended March 31, 2022. The same has been circulated to the Directors, Key Managerial Personnel, Employees of the Company and their immediate relatives. Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held on 16.05.2022 at 03.00 p.m. considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended 31.03.2022 along with Statement of Assets and Liabilities and cash flow statement as on that date. a. A copy of the said Financial Results along with the Auditors Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 of SEBI (LODR) Regulations, 2015. 2. The Audited Standalone Financial Statements for the Financial Year ended March 31, 2022. 3. Recommended Final Dividend at 7% per Equity Share having face value of Rs. 10/- each for the Financial Year 2021-22; subject to the approval of the shareholders at the ensuing AGM of the Company; The Board Meeting commenced at 03.00 p.m. and concluded at 6:45 p.m. (As Per BSE Announcement Dated on 16.05.2022)
Board Meeting - 08-Apr-2022 - -
We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), at their Meeting held on Friday, 08th April, 2022 at 11:00 am had considered and approved the following items of Business: 1. Appointment of Ms. Kala Agarwal, Practising Company Secretary as Secretarial Auditor of the Company to conduct Secretarial Audit for the Financial Year 2021-2022. The Meeting of the Board Commenced at 11:00 A.M. and concluded at 12:15 P.M. Kindly oblige and take the same on your Records. We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), at their Meeting held on Friday, 08th April, 2022 at 11:00 am had considered and approved the following items of Business: 1. Appointment of Ms. Kala Agarwal, Practising Company Secretary as Secretarial Auditor of the Company to conduct Secretarial Audit for the Financial Year 2021-2022. The Meeting of the Board Commenced at 11:00 A.M. and concluded at 12:15 P.M. Kindly oblige and take the same on your Records.
Board Meeting - 19-Jan-2022 - -
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2022 inter alia to consider and approve Pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Friday 28th January 2022 at 3.00 pm at the Registered Office of the Company to transact inter - alia the following businesses: 1) To discuss consider and approve Unaudited Financial Results of the Company for the Quarter ended December 31st 2021. 2) Any other matter with the permission of the Chair Further in continuation of our intimation dated 31st December 2021 and pursuant to Companys Code of Conduct for Prevention of Insider Trading the Trading Window for dealing in the securities of the Company is closed from 1st January 2022 till 30th January 2022 (both days inclusive). The same has been circulated to the Directors Key Managerial Personnel and Employees of the Company. We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), at their Meeting held on Friday, 28th January 2022 at 3:00 pm had considered and approved the following items of Business: 1. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; the Un-Audited Financial Results of the Company for the quarter ended December 31st, 2021; along with the Limited Review Report as issued by M/s Savla & Associates; Statutory Auditors of the Company; copies of which are attached hereunder; 2. Appointment of Ms. Jinkal Shah as a Company Secretary and Compliance Officer of the Company with effect from 28th January, 2022. We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), at their Meeting held on Friday, 28th January 2022 at 3:00 pm had considered and approved the following items of Business: 1. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; the Un-Audited Financial Results of the Company for the quarter ended December 31st, 2021; along with the Limited Review Report as issued by M/s Savla & Associates; Statutory Auditors of the Company; copies of which are attached hereunder; 2. Appointment of Ms. Jinkal Shah as a Company Secretary and Compliance Officer of the Company with effect from 28th January, 2022. (As Per BSE Announcement Dated on 28.01.2022)
Board Meeting - 17-Nov-2021 - -
Dear Sirs, This is with reference to the in-principle approval granted by your good office vide letter No. DCS/PREF/JR/PRE/1652/2021-22 dated November 17, 2021 Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at their meeting held on 17th November, 2021 at 6.30 pm has allotted 2,46,374 Equity Shares at a price of Rs. 422.10/- each and 2,16,771 Convertible Warrants at a price of Rs. 422.10/- each by way of Preferential Issue. The requisite details as required in terms of SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015 are provided at Annexure I. Further the meeting was concluded at 6:55 P.M. Kindly take the aforesaid information on your records.
Board Meeting - 01-Nov-2021 - -
Quarterly Results We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), at their Meeting held on Saturday, 6th November, 2021 at 3:00 pm had considered and approved the following items of Business: 1. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; the Un-Audited Financial Results of the Company for the quarter ended September 30, 2021; along with the Limited Review Report as issued by M/s Savla & Associates; Statutory Auditors of the Company; copies of which are attached hereunder; The Meeting of the Board Commenced at 3:00 P.M. and concluded 4:00 P.M. Kindly oblige and take the same on your Records. We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), at their Meeting held on Saturday, 6th November, 2021 at 3:00 pm had considered and approved the following items of Business: 1. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; the Un-Audited Financial Results of the Company for the quarter ended September 30, 2021; along with the Limited Review Report as issued by M/s Savla & Associates; Statutory Auditors of the Company; copies of which are attached hereunder; The Meeting of the Board Commenced at 3:00 P.M. and concluded at 4.00 P.M. Kindly oblige and take the same on your Records. (As Per BSE Announcement Dated on 06.11.2021)
Board Meeting - 15-Sep-2021 - -
This is to inform you that a meeting of the Board of Directors is scheduled to be held on Saturday 18th September 2021 at 11:00am to consider the following: 1. Issue of equity shares/warrants/fully convertible debentures or any other financial instrument which would be converted into / exchanged with equity shares at a later date under Preferential Guidelines of SEBI to promoters and other eligible investors 2. To consider and approve the matter of holding an EGM/Postal Ballot 3. To consider the matter of making an application to BSE for in-principle approval 4. Any other matter with the permission of the Chair The meeting of Board of Directors pursuant to Regulation 29 of the Listing Regulations shall be held on Wednesday, September 22, 2021 to consider and evaluate proposals for raising of funds in one or more tranches by issuing one or more instruments comprising of Equity Shares, convertible securities of any other description or warrants, through Preferential Issue as may be decided by the Board to Promoters and Non Promoters, subject to such statutory/ regulatory approvals as may be necessary including the approval of shareholders of the Company, wherever required. (As Per BSE Announcement dated on 18.09.2021) Further to our intimation dated Wednesday, September 15, 2021 to consider the option of fund raising through Preferential Issue, the Board Meeting was held on Saturday, September 18, 2021 and Outcome of the same in terms of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) was uploaded; wherein it was mentioned that the meeting was deferred and scheduled for Wednesday, September 22, 2021 due to heavy interest from various investors and certain investors had asked some more time to give their details. In furtherance to the same kindly find enclosed the outcome of meeting of Board of Directors held today i.e. Wednesday, September 22, 2021 in accordance with Listing Regulations. (As Per BSE Announcement dated on 22.09.2021)
Board Meeting - 04-Aug-2021 - -
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, August 10, 2021 at 3:00 P.M. at the Registered Office of the Company. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; we submit the Un-Audited Financial Results of the Company for the quarter ended June 30, 2021; along with the Limited Review Report as issued by M/s Savla & Associates; Statutory Auditors of the Company. (As per BSE Announcement Dated on 10/8/2021)
Board Meeting - 19-Jun-2021 - -
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/06/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Monday, June 28, 2021 at 3:00 P.M. at the Registered Office of the Company Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. 28th June, 2021 has inter-alia, considered, adopted and approved Audited Financial Results of the Company for the fourth quarter and financial year ended 31st March, 2021. A copy of Audited Financial Results along with Auditors Report thereon is enclosed herewith. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. 28th June, 2021 has inter-alia, considered, adopted and approved Audited Financial Results of the Company for the fourth quarter and financial year ended 31st March, 2021. A copy of Audited Financial Results along with Auditors Report thereon is enclosed herewith. (AS Per BSE Announcement Dated on 28.06.2021) The Board of Directors of the Company at its meeting today i.e. 28th June, 2021 has recommended Dividend of Rs. 0.7/- per share of Rs. 10 each (7 %) for the financial year ended 31st March, 2021 subject to approval of the Shareholders at the ensuing Annual General Meeting of the Company. (As Per BSE Announcement Dated on 29.06.2021) In compliance to Regulation 47(1)(b) of SEBI Listing Regulations, 2015; we enclose herewith the copies of the Newspaper cuttings of the Financials Results of the Company for the Quarter and Year ended March 31 2021; as approved by the Board in its Meeting held on Monday, June 28, 2021; published in Business Standard & Mumbai Lakshadeep newspaper(s) on Wednesday, June 30, 2021. (As Per BSE Announcement Dated 01.07.2021)
Board Meeting - 11-Jun-2021 - -
In compliance to Regulation 30 of SEBI Listing Regulations, 2015; we wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), at their Meeting held on Friday, June 11, 2021; at 10.30 a.m. had considered and approved various business opportunities of the Company and discussed the other General Matters related to the Company.
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity